Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | UNK | — | OT |
feeling badly; missed second dose of pre-exposure imovax therapy due to feeling badly; Initial information received on 24-Jun-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves an unknown age female patient who had missed second dose of pre-exposure Rabies (Hdc) Vaccine [Imovax Rabies] therapy due to feeling badly. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, caller stated that the patient missed second dose of pre exposure suspect Rabies (Hdc) Vaccine, Powder and solvent for suspension for injection, (lot number, expiry date and strength not reported) for Immunization therapy due to feeling badly (routine immunisation schedule incomplete) (unknown latency). Information on the batch number was requested corresponding to the one at time of event occurrence On an unknown date the patient was feeling badly (feeling abnormal) (unknown latency). Reportedly,patient missed second dose on day 7, now day 11. Pharmacist stated patient missed second dose of preexposure IMOVAX therapy due to feeling badly. She stated it is now day 11 and pharmacist requested recommendation for schedule of second dose. HCP (health care professional) stated patient has no fever, is under the weather like her children, has a sore throat, and it is not related to Imovax injection. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event Feeling abnormal. At time of reporting, the outcome was Unknown for the event Feeling abnormal. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.